Centre Hospitalier Pierre Oudot
- Address
- lock Available on a paid plan
Oncology and Hematologic Malignancies
At Centre Hospitalier Pierre Oudot, clinical research in oncology includes studies on multiple myeloma, focusing on newly diagnosed older adults who are not eligible for transplant. The trials are designed to assess how well new treatment combinations control disease and reduce minimal residual disease.
- Evaluating treatment effectiveness in newly diagnosed multiple myeloma for older patients
- Studying hematologic diseases with a focus on disease control and response
- Testing whether adding therapies can improve outcomes for non-frail patients
This research aims to improve care for people with blood cancers by identifying better ways to manage the disease in a population with specific treatment needs.
Digestive System Diseases
The site is also conducting trials in digestive system diseases, especially rectal adenocarcinoma. These studies explore ways to preserve the organ while maintaining strong cancer control, using approaches intended to improve survival and quality of life.
- Investigating rectal cancer treatment strategies aimed at organ preservation
- Assessing new options for selected patients with intermediate-risk rectal adenocarcinoma
- Supporting research on better local control and long-term outcomes in gastrointestinal cancers
These trials focus on refining care for patients with rectal cancer by comparing treatment approaches that may help preserve function without compromising effectiveness.
Neoplasms in Older Adults
Research at Centre Hospitalier Pierre Oudot also addresses colon cancer and other solid tumors in patients aged 70 and over. The studies are intended to determine whether different post-surgery treatment strategies can improve relapse-free survival.
- Comparing treatment approaches after surgery for stage III colon cancer
- Studying cancer outcomes in older adults after colon adenocarcinoma resection
- Evaluating ways to reduce recurrence and extend relapse-free survival
This work supports better decision-making for older patients with neoplasms, where the goal is to balance cancer control with practical treatment choices.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centre Hospitalier Pierre Oudot
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Phase 3 Study of Isatuximab, Lenalidomide, and Dexamethasone ± Bortezomib in Non-Frail, Transplant-Ineligible Elderly Patients with Newly Diagnosed Multiple Myeloma | Centre Hospitalier Universitaire De Poitiers | Phase III | Not Recruiting | Jun 2021 | — |
IMP list
lock Showing 1 of 9 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Bortezomib | 1 | Unknown | 2021-06-11 | 2021-06-11 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.